Sentences with phrase «scientists at pharmaceutical companies»

Scientists at pharmaceutical companies, the National Cancer Institute, and laboratories at Hopkins and other universities are investigating whether drugs that inhibit HIF - 1 may be useful for cancer therapy.

In his role as researcher, he developed a potential drug to treat different types of immune diseases and was able to accompany the molecule through the next stages?something most scientists at pharmaceutical companies are not able to do.

On the industry side, Lilly, headquartered in Indianapolis, Indiana, has a program that encourages scientists at the pharmaceutical company to collaborate with university researchers.

Not exact matches

The scale that scientists use to describe a chili's heat was developed in 1912 by Wilbur Scoville, a chemist at Parke - Davis pharmaceutical company in Detroit.

After 14 years in the United States, as a student and as a scientist at a big pharmaceutical company, medicinal chemist Kamil Paruch (pictured at top) decided to return to his native Czech Republic.

So, I took a job as a research scientist in the analytical lab of a smaller chemistry - driven, discovery - based pharmaceutical company located in Vancouver, B.C. With fewer than 100 employees and no products on the market, it couldn't have been further from the formal corporate work environment I was accustomed to at a multinational company.

This year like all others, scientists want to work at companies that keep innovation front and center, and the top 20 employers in 2015 include those biotechnology and pharmaceutical firms on the leading edge of these advances.

«With the headcount constraints in today's economic climate, industry needs to hire leaders as well as technically excellent scientists,» says Scott Reines, newly retired vice president of pharmaceutical research and development at Johnson & Johnson, a pharmaceutical company based in New Brunswick, New Jersey.

With the proper clearance, bench scientists at the NIH should have the right «to do what every other scientist has the right to do: consult for a science advisory committee or a pharmaceutical company or a biotech company, partly because that's become part of the culture and partly because it's very much a two - way exchange,» Alberts says.

He's consulting with Boehringer Ingelheim, a pharmaceutical company headquartered in Germany, where scientists this fall began offering an experimental drug to people at very high risk of psychosis who are eligible based on the severity of their symptoms.

The biotechnology and pharmaceutical industry usually pops up first in many people's minds, with companies in that sector continuing to hire scientists at both the B.S. and M.S. levels.

But I think it's a disservice to gloss over the topic, because in reality it can be a fairly large hurdle for a successful industry transition,» said Andrew Spencer, a research scientist at Alvine Pharmaceuticals who has experience at biotech companies and small start - ups.

These include government or private nonprofit funders of basic research, such as the National Institutes of Health in the United States or the Wellcome Trust in the United Kingdom; academic scientists; multinational pharmaceutical firms and smaller biotech companies; and, at the end of the line, government regulatory agencies responsible for drug approval.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs.

C. Glenn Begley, who spent a decade in charge of global cancer research at the biotech giant Amgen, recently dispatched 100 Amgen scientists to replicate 53 landmark experiments in cancer — the kind of experiments that lead pharmaceutical companies to sink millions of dollars to turn the results into a drug.

Today, CCP4 has around 2 million lines of code, dozens of active contributors and thousands of users worldwide, including expert crystallographers, academic researchers interested in solving structures, and scientists doing drug development at pharmaceutical companies.

The Center would represent a hub to connect scientists and physicians at universities, research institutions, medical centers, and pharmaceutical companies.

He has also served as Director for Cancer Immunology and Immunotherapy for the Donald Monk Cancer Research Foundation; he is a partner at Veterinary Research Associates, LLC, a company focused on development and implementation of diagnostics for veterinary medicine and a founder / scientist at ApopLogic Pharmaceuticals, Inc, a biotechnology company focused on development of cancer therapeutics.